tuneTypical Dose
1.6–2.4 g/day
Amino Acid
Taurine
2-aminoethanesulfonic acid
Evidence TierCWADA NOT PROHIBITED
watchEffect Window
2–12 weeks for repeated-dose CV/metabolic effects; acute effects within hours in specific performance studies
check_circleCompliance
WADA NOT PROHIBITED
Overview
Clinical Summary
Taurine is a sulfur-containing amino acid involved in bile acid conjugation, osmoregulation, and calcium handling. It is used for cardiometabolic biomarker support and for exercise recovery and endurance goals.
Trials show modest blood pressure reductions and improvements in some glucose and lipid biomarkers, consistent with taurine roles in vascular tone and metabolism. A 2024 meta-analysis in adults with overweight or obesity found the clearest signal for better HbA1c, fasting glucose, insulin resistance, and fasting insulin at longer durations and around 3 g/day. Exercise studies suggest reduced muscle damage and occasional endurance improvements, but performance effects remain less reliable than the metabolic signal.
Osmoregulation, endothelial/autonomic signaling, and mitochondrial/metabolic modulation are proposed; clinical confidence strongest for vascular endpoints, weaker for direct cognitive claims.
Outcomes
What This Is Expected To Influence
Primary Outcomes
- Blood pressure and vascular-function endpoints show modest improvement in RCT/meta-analytic adult data.
- Heart-failure exercise capacity shows directionally favorable short-term changes in small trials.
Secondary Outcomes
- No consistent standalone cognition enhancement; effects are mixed and generally small.
- Acute endurance performance in healthy athletes is not reliably improved.
Safety
Contraindications and Interactions
Contraindications
- Pregnancy/lactation
- Active severe renal/hepatic impairment
- Unstable heart failure
- Severe psychiatric instability
- Known unstable arrhythmias
Side effects
- Mild GI effects (including nausea)
- Headache
- Dizziness (uncommon)
Interactions
- Blood-pressure-lowering drugs (Theoretical/Unknown) - Potential additive hypotensive effects; monitor blood pressure, symptoms, and hemodynamics in higher-risk users.
- Blood-pressure-lowering supplements (Theoretical/Unknown) - Additive hemodynamic effects are possible with multi-agent stacks; avoid unmonitored combinations.
- Stimulatory cardiometabolic stacks (Theoretical/Unknown) - Combined autonomic/hemodynamic effects may increase palpitations or blood-pressure variability; avoid unmonitored multi-agent use.
Avoid if
- Pediatric use without specialist oversight
- Uncontrolled hypertension without monitoring
- Active unstable heart failure
- Active malignancy protocols without specialist review
Evidence
Study-level References
taurine-SRC-001Randomized, double-blind, placebo-controlled parallel RCT
Sourceopen_in_newSun Q et al. *Taurine Supplementation Lowers Blood Pressure and Improves Vascular Function in Prehypertension*. PMID: 26781281, DOI: 10.1161/HYPERTENSIONAHA.115.06624
Population: 120 adults with prehypertension, 12-week intervention
Dose protocol: 1.6 g/day taurine vs placebo
Key findings: Favorable directional reduction in clinic and 24-h BP (greater in higher baseline BP subgroup) Clinically meaningful BP reduction versus placebo; vascular surrogate improvements support consistency with autonomic/endothelial hypotheses.
Paper content
Favorable directional reduction in clinic and 24-h BP (greater in higher baseline BP subgroup) Clinically meaningful BP reduction versus placebo; vascular surrogate improvements support consistency with autonomic/endothelial hypotheses.
taurine-SRC-002RCT
Sourceopen_in_newLi Y, Wang Q, Liu Y, et al. Taurine ameliorates blood pressure and vascular function in patients with type 2 diabetes: Randomized, double-blind, placebo-controlled trial. iScience. 2025;28(6):112719. doi:10.1016/j.isci.2025.112719. PMID:40546935.
Population: Patients with type 2 diabetes
Dose protocol: 2.4 g/day
Key findings: Favorable direction with improvements in systolic BP, endothelial/vascular function indices, and pulse wave velocity trends Supports potential vascular-metabolic adjunct role of taurine in T2D populations.
Paper content
This RCT of 165 type 2 diabetes patients found that 12 weeks of taurine supplementation (2.4 g/day) significantly reduced systolic blood pressure, improved endothelium-dependent and -independent vasodilation, improved pulse wave velocity, and inhibited platelet calcium influx compared to placebo.
taurine-SRC-003Meta-analysis (human RCTs)
Sourceopen_in_newHsieh C et al. *Effects of Oral Taurine Supplementation on Cardiometabolic Risk Factors: A Meta-analysis and Systematic Review of Randomized Clinical Trials*. PMID: 41275513, DOI: 10.1093/nutrit/nuaf220
Population: Mixed adult RCTs across cardiometabolic outcomes
Dose protocol: Mostly 1.6–6 g/day, variable durations
Key findings: Small-to-moderate pooled reductions in BP, glucose, insulin resistance, triglycerides, and total/LDL cholesterol Suggests directional but modest cardiometabolic benefits; stronger signal for some markers than for clinical event-level outcomes.
Paper content
Small-to-moderate pooled reductions in BP, glucose, insulin resistance, triglycerides, and total/LDL cholesterol Suggests directional but modest cardiometabolic benefits; stronger signal for some markers than for clinical event-level outcomes.
taurine-SRC-004Randomized, single-blind, placebo-controlled trial
Sourceopen_in_newBeyranvand MR et al. *Effect of taurine supplementation on exercise capacity of patients with heart failure*. PMID: 21334852, DOI: 10.1016/j.jjcc.2011.01.007
Population: Adults with chronic heart failure (n=29), 2-week intervention
Dose protocol: 500 mg three times daily
Key findings: Directionally favorable short-term change in exercise tolerance indices (exercise time, METS, distance) Functional signal without severe adverse signal, but limited strength for robust guidance.
Paper content
Directionally favorable short-term change in exercise tolerance indices (exercise time, METS, distance) Functional signal without severe adverse signal, but limited strength for robust guidance.
taurine-SRC-005Randomized, double-blind, placebo-controlled crossover trial
Sourceopen_in_newRutherford JA et al. *The effect of acute taurine ingestion on endurance performance and metabolism in well-trained cyclists*. PMID: 20739720, DOI: 10.1123/ijsnem.20.4.322
Population: 11 trained cyclists, acute pre-exercise supplementation
Dose protocol: Single 1.66 g dose 1 hour before cycling
Key findings: No meaningful TT performance gain; modest fat oxidation increase during exercise Performance endpoints not robustly improved in healthy athlete setting.
Paper content
No meaningful TT performance gain; modest fat oxidation increase during exercise Performance endpoints not robustly improved in healthy athlete setting.
taurine-SRC-006Meta-analysis (human RCTs)
Sourceopen_in_newCao Q et al. *Effects of taurine supplementation on cognitive function: a systematic review and meta-analysis of randomised controlled trials*. PMID: 40320621, DOI: 10.1080/09637486.2025.2499044
Population: 7 RCTs, 9 intervention trials, 402 participants
Dose protocol: Mixed, often 1–3 g/day regimens and some combination regimens
Key findings: Overall no strong standalone cognition signal; mixed small subgroup effect with combination therapy Current evidence does not support strong confidence in cognition as a primary taurine claim.
Paper content
Overall no strong standalone cognition signal; mixed small subgroup effect with combination therapy Current evidence does not support strong confidence in cognition as a primary taurine claim.
taurine-SRC-007Double-blind randomized crossover trial
Sourceopen_in_newAzuma J et al. *Therapeutic effect of taurine in congestive heart failure: a double-blind crossover trial*. PMID: 3888464, DOI: 10.1002/clc.4960080507
Population: Adults with CHF (n=14 in intervention period)
Dose protocol: 500 mg three times daily for 4 weeks
Key findings: Directionally favorable NYHA and symptom-related changes; no modern replication in large RCTs Historically interesting but low confidence for current guidance.
Paper content
Directionally favorable NYHA and symptom-related changes; no modern replication in large RCTs Historically interesting but low confidence for current guidance.
taurine-SRC-008Regulatory risk/safety opinion
Sourceopen_in_newEuropean Food Safety Authority (EFSA) FEEDAP. *Taurine for all animal species* (2012 opinion with human exposure context), https://www.efsa.europa.eu/sites/default/files/scientific_output/files/main_documents/2736.pdf
Population: Cross-species safety panel with human-exposure context
Dose protocol: Exposure/safety framework (human exposure estimate, observed safe level discussion)
Key findings: Sets an upper observed safe exposure context (reported as ~6 g/person/day) but does not establish disease-treatment efficacy Useful for upper-bound safety framing; efficacy requires human RCT evidence.
Paper content
Sets an upper observed safe exposure context (reported as ~6 g/person/day) but does not establish disease-treatment efficacy Useful for upper-bound safety framing; efficacy requires human RCT evidence.
taurine-SRC-009Systematic review and meta-analysis of randomized controlled trials
Sourceopen_in_newSun Q, et al. Effect of long-term taurine supplementation on the lipid and glycaemic profile in adults with overweight or obesity. A systematic review and meta-analysis. Nutrients. 2024;17(1):55. doi:10.3390/nu17010055. PMID:39796489.
Population: Adults with overweight or obesity
Dose protocol: 9 RCTs in adults with overweight or obesity, with stronger glycemic effects around 3 g/day.
Key findings: Meta-analysis found improved fasting insulin, triglycerides, total cholesterol, and obesity-specific HbA1c and HOMA-IR outcomes, with better glycemic control at 3 g/day.
Notes: Strengthens taurine's metabolic positioning more than its performance positioning.
Paper content
Taurine meta-analysis in adults with overweight or obesity found the clearest signal for glycemic control and insulin sensitivity, particularly in obesity and at 3 g/day. Lipid changes were favorable but modest.
taurine-SRC-010Narrative review of randomized crossover trials.
Sourceopen_in_newNaddafha S, Stout JR, Evans C. Taurine Supplementation and Human Heat Tolerance: Mechanisms, Evidence, and Integration with Heat Acclimation, Cooling, and Hydration. Nutrients. 2026;18(4):592. doi:10.3390/nu18040592. PMID:41754109.
Population: Healthy adults performing exercise in heat stress conditions.
Dose protocol: ~50 mg/kg acute or short-term multi-day dosing in heat stress exercise contexts
Key findings: Narrative review of crossover trials found earlier sweat onset, higher sweat production, and modestly lower core temperature (0.3 to 0.4 degrees C) with taurine during heat stress exercise. Benefits were context-dependent.
Notes: Adds a thermoregulatory dimension to taurine's exercise profile, though evidence remains limited by small sample sizes.
Paper content
This narrative review synthesizes evidence from randomized crossover trials on taurine supplementation during heat-intensive exercise. Acute dosing at roughly 50 mg/kg or short multi-day regimens was associated with earlier sweat onset, greater sweat production, modestly lower core temperature (approximately 0.3 to 0.4 degrees C), and enhanced exercise capacity in some heat stress contexts. Benefits appeared situation-specific and diminished when perspiration was restricted (such as with protective gear) or when heat acclimation was already optimized. The review notes that increased perspiration from taurine requires coordinated fluid and electrolyte replacement. Evidence remains limited by small sample sizes and methodological variability across the included trials.
taurine-SRC-011Narrative review.
Sourceopen_in_newHossain MK, Kim HR. Taurine as an Early-Phase Disease-Modifying Candidate for Alzheimer's Disease. Int J Mol Sci. 2026;27(4):1871. doi:10.3390/ijms27041871. PMID:41752008.
Population: Preclinical and translational evidence relevant to Alzheimer's disease pathology.
Dose protocol: Preclinical and translational review, no specific human dosing
Key findings: Positions taurine as a pleiotropic neuroprotector with activity across amyloid, tau, oxidative, mitochondrial, and neuroinflammatory Alzheimer's pathways. No human AD data reported.
Notes: Adds mechanistic context for neurological interest but does not change clinical confidence for cognition claims.
Paper content
This review positions taurine as a pleiotropic neuroprotector with the potential to modulate multiple Alzheimer's disease pathways simultaneously, including amyloid-beta aggregation, oxidative stress, mitochondrial dysfunction, neuroinflammation, and synaptic loss. The authors argue that because these pathological processes begin decades before clinical symptoms appear, early intervention with taurine could be a meaningful upstream strategy. The biological rationale is supported by taurine's endogenous abundance and established clinical safety profile. However, this remains a mechanistic and preclinical review. No human Alzheimer's prevention or treatment trials with taurine are reported, so clinical translation remains entirely speculative at this stage.